Atherogenic remnant lipoproteins: Role for proteoglycans in trapping, transferring, and internalizing

Journal of Clinical Investigation

Volumn 117, Issue 1, 2007, Pages 94-98

  Mahley, Robert W ^a,b,c   Huang, Yadong ^a,b,c  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; APOLIPOPROTEIN E; CHYLOMICRON; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROTEOHEPARAN SULFATE; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; BINDING AFFINITY; CELL SURFACE; HYPERCHOLESTEROLEMIA; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LIPOPROTEINS; LIVER; MODELS, BIOLOGICAL; PROTEOGLYCANS; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 33846007667     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30889     Document Type: Review

References (38)

1. Mahley, R.W., and Ji, Z.-S. 1999. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40:1-16.
2. Mahley, R.W., Huang, Y., and Rall, S.C., Jr. 1999. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J. Lipid Res. 40:1933-1949.
3. Mahley, R.W., Weisgraber, K.H., Innerarity, T.L., and Rall, S.C., Jr. 1991. Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA. 265:78-83.
4. Mahley, R.W., and Rall, S.C., Jr. 1995. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The metabolic and molecular bases of inherited disease. 7th edition. Volume 2. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill. New York, New York, USA. 1953-1980.
5. Mahley, R.W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:622-630.
6. Williams, K.J., et al. 1992. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J. Biol. Chem. 267:13284-13292.
7. Williams, K.J., and Fuki, I.V. 1997. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr. Opin. Lipidol. 8:253-262.
8. Ji, Z.-S., Dichek, H.L., Miranda, R.D., and Mahley, R.W. 1997. Heparan sulfate proteoglycans participate in hepatic lipase- and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J. Biol. Chem. 272:31285-31292.
9. Zheng, C., Murdoch, S.J., Brunzell, J.D., and Sacks, F.M. 2006. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 26:891-896.
10. Mahley, R.W., et al. 1989. Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J. Clin. Invest. 83:2125-2130.
11. Shimano, H., et al. 1994. Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice. J. Clin. Invest. 93:2215-2223.
12. Fan, J., et al. 1998. Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma. J. Clin. Invest. 101:2151-2164.
13. Huang, Y., et al. 1999. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler. Thromb. Vasc. Biol. 19:2952-2959.
14. Ishibashi, S., et al. 1996. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J. Biol. Chem. 271:22422-22427.
15. Plump, A.S., et al. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
16. Zhang, S.H., Reddick, R.L., Piedrahita, J.A., and Maeda, N. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
17. Huang, Y., Rall, S.C., Jr., and Mahley, R.W. 1997. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler. Thromb. Vasc. Biol. 17:2817-2824.
18. Horie, Y., Fazio, S., Westerlund, J.R., Weisgraber, K.H., and Rall, S.C., Jr. 1992. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J. Biol. Chem. 267:1962-1968.
19. Fazio, S., Lee, Y.-L., Ji, Z.-S., and Rall, S.C., Jr. 1993. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. J. Clin. Invest. 92:1497-1503.
20. Ji, Z.-S., Fazio, S., and Mahley, R.W. 1994. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269:13421-13428.
21. Ji, Z.-S., et al. 1993. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J. Biol. Chem. 268:10160-10167.
22. Raffaï, R.L., et al. 2003. Hepatocyte-derived apoE is more effective than non-hepatocyte-derived apoE in remnant lipoprotein clearance. J. Biol. Chem. 278:11670-11675.
23. Kita, T., et al. 1982. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 79:3623-3627.
24. Rubinsztein, D.C., et al. 1990. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1306-1312.
25. Herz, J., and Willnow, T.E. 1995. Lipoprotein and receptor interactions in vivo. Curr. Opin. Lipidol. 6:97-103.
26. Rohlmann, A., Gotthardt, M., Hammer, R.E., and Herz, J. 1998. Inducible inactivation of hepatic LRP gene by Cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:689-695.
27. Ji, Z.-S., Fazio, S., Lee, Y.-L., and Mahley, R.W. 1994. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. J. Biol. Chem. 269:2764-2772.
28. Ji, Z.-S., Sanan, D.A., and Mahley, R.W. 1995. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J. Lipid Res. 36:583-592.
29. Fuki, I.V., et al. 1997. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 100:1611-1622.
30. Zeng, B.-J., Mortimer, B.-C., Martins, I.J., Seydel, U., and Redgrave, T.G. 1998. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J. Lipid Res. 39:845-860.
31. Wilsie, L.C., and Orlando, R.A. 2003. The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism. J. Biol. Chem. 278:15758-15764.
32. MacArthur, J.M., et al. 2007. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 117:153-164. doi:10.1172/ JCI29154.
33. Bernfield, M., et al. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68:729-777.
34. Esko, J.D., and Selleck, S.B. 2002. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71:435-471.
35. Jones, C., et al. 2007. Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J. Clin. Invest. 117:165-174. doi:10.1172/JCI29415.
36. Garcia, C.K., et al. 2001. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 292:1394-1398.
37. Jones, C., et al. 2003. Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. J. Biol. Chem. 278:29024-29030.
38. He, G., et al. 2002. ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. J. Biol. Chem. 277:44044-44049.